Concepts (77)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 9 | 2025 | 183 | 2.680 |
Why?
|
| Multifactorial Inheritance | 1 | 2025 | 26 | 0.900 |
Why?
|
| Systemic Vasculitis | 1 | 2024 | 3 | 0.880 |
Why?
|
| Gene-Environment Interaction | 1 | 2025 | 53 | 0.870 |
Why?
|
| Antibodies, Antinuclear | 1 | 2024 | 41 | 0.860 |
Why?
|
| Environmental Exposure | 1 | 2025 | 226 | 0.780 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2022 | 16 | 0.750 |
Why?
|
| Lupus Nephritis | 1 | 2023 | 37 | 0.740 |
Why?
|
| Myasthenia Gravis | 2 | 2020 | 12 | 0.720 |
Why?
|
| Interleukins | 2 | 2020 | 87 | 0.710 |
Why?
|
| Kidney Failure, Chronic | 1 | 2023 | 196 | 0.670 |
Why?
|
| Thymus Gland | 1 | 2018 | 240 | 0.520 |
Why?
|
| Incidence | 5 | 2024 | 1418 | 0.520 |
Why?
|
| Prevalence | 4 | 2024 | 1445 | 0.470 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 563 | 0.450 |
Why?
|
| Minnesota | 3 | 2023 | 45 | 0.430 |
Why?
|
| Adult | 10 | 2025 | 17356 | 0.350 |
Why?
|
| Rheumatology | 2 | 2022 | 70 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2025 | 730 | 0.330 |
Why?
|
| Middle Aged | 6 | 2025 | 18267 | 0.250 |
Why?
|
| Humans | 16 | 2025 | 65124 | 0.250 |
Why?
|
| Male | 10 | 2025 | 31042 | 0.240 |
Why?
|
| Female | 11 | 2025 | 34016 | 0.240 |
Why?
|
| United Kingdom | 1 | 2025 | 85 | 0.220 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2024 | 10 | 0.220 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2024 | 4 | 0.220 |
Why?
|
| Age of Onset | 1 | 2025 | 174 | 0.220 |
Why?
|
| Asymptomatic Diseases | 1 | 2024 | 52 | 0.220 |
Why?
|
| Young Adult | 4 | 2023 | 4810 | 0.200 |
Why?
|
| Leukopenia | 1 | 2023 | 16 | 0.200 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2023 | 18 | 0.200 |
Why?
|
| Pericarditis | 1 | 2022 | 10 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 56 | 0.190 |
Why?
|
| Fibromyalgia | 1 | 2022 | 15 | 0.190 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 361 | 0.190 |
Why?
|
| Hyperlipidemias | 1 | 2022 | 34 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2022 | 2619 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 509 | 0.180 |
Why?
|
| Case-Control Studies | 1 | 2025 | 1141 | 0.180 |
Why?
|
| Retinal Diseases | 1 | 2022 | 34 | 0.180 |
Why?
|
| Lung Diseases | 1 | 2023 | 183 | 0.180 |
Why?
|
| Osteoporosis | 1 | 2022 | 113 | 0.170 |
Why?
|
| Fractures, Bone | 1 | 2022 | 138 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 151 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 142 | 0.160 |
Why?
|
| Antimalarials | 1 | 2021 | 126 | 0.160 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2020 | 6 | 0.160 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2020 | 41 | 0.160 |
Why?
|
| Risk Factors | 3 | 2025 | 5429 | 0.160 |
Why?
|
| Interleukin-4 | 1 | 2020 | 147 | 0.160 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 380 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 64 | 0.150 |
Why?
|
| Antirheumatic Agents | 1 | 2022 | 227 | 0.150 |
Why?
|
| Interleukin-17 | 1 | 2020 | 99 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2023 | 6862 | 0.140 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2021 | 346 | 0.130 |
Why?
|
| Aged | 3 | 2025 | 14958 | 0.130 |
Why?
|
| Hypertension | 1 | 2022 | 612 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 637 | 0.120 |
Why?
|
| Hospitalization | 1 | 2022 | 1392 | 0.110 |
Why?
|
| Adolescent | 3 | 2022 | 6305 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2018 | 2188 | 0.100 |
Why?
|
| Child | 2 | 2022 | 4612 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 5612 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 159 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 2022 | 19 | 0.050 |
Why?
|
| Social Perception | 1 | 2022 | 44 | 0.050 |
Why?
|
| Recurrence | 1 | 2023 | 657 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2023 | 285 | 0.040 |
Why?
|
| Receptors, Cholinergic | 1 | 2020 | 24 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2022 | 235 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2020 | 184 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 325 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 497 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 526 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2020 | 3149 | 0.020 |
Why?
|
| United States | 1 | 2022 | 8097 | 0.020 |
Why?
|